CLEVELAND, Ohio (July 15, 2026) — Perimenopause remains an underrecognized biological transition marked by hormone-driven symptom volatility. A new US study quantifies how common “perimenopause uncertainty” is and identifies its main drivers, with findings published online today in Menopause, the journal of The Menopause Society. The work reframes an often individual experience as a measurable, population-level phenomenon shaped by information access and healthcare interactions.
Perimenopause is the reproductive transition leading up to the final menstrual period, typically beginning in mid-40s, though onset varies. In the United States, an estimated two million women enter perimenopause annually and typically remain in this stage for 4 to 8 years. Despite the scale of this transition, reliable staging remains elusive.
A core challenge is the absence of a laboratory test or biomarker that definitively assigns perimenopause stage. Symptom patterns also evolve over time and overlap with other diagnoses, including premenstrual syndrome, thyroid disorders, and mental health conditions. As a result, recognition often depends on how people interpret symptoms rather than on objective measurement.
The researchers surveyed more than 7,600 women aged 35 and older to estimate uncertainty prevalence and evaluate differences by age and symptom severity. Overall, 34% of participants reported being unsure of their reproductive stage. Rates were highest among women aged 40 to 44 years (42%) and among those with severe symptom burden (37%).
To pinpoint uncertainty mechanisms, participants described symptom confusion and attribution (56%) as the leading contributor—reflecting difficulty distinguishing perimenopause-related changes from other causes. Knowledge gaps and information-seeking followed (28%), suggesting limited health literacy, reliance on age-based assumptions, and active searching for evidence. Barriers to confirmation and care accounted for 16%, including dismissive clinical encounters and reluctance to acknowledge perimenopause.
The study also highlights age-dependent differences in these drivers. Women aged 35 to 39 were more likely to cite knowledge gaps, while healthcare barriers peaked in the 40 to 44 group. Collectively, the findings suggest uncertainty is not random but structured by both cognitive interpretation and system-level support.
Clinicians are encouraged to adopt a multidimensional framework that normalizes cognitive, emotional, and physical changes earlier in the transition. Rather than over-relying on menstrual irregularity, practitioners should recognize that symptoms may precede clear cycle changes—an approach aligned with the study’s emphasis on real-world diagnostic ambiguity.
By treating perimenopause uncertainty as common and explainable, the research aims to shift conversations from searching for a definitive label toward providing validated education and supportive care during the menopause transition.
Subject of Research: People
Article Title: exploring prevalence and drivers of perimenopause uncertainty among US Women: a mixed-methods study
News Publication Date: 15-Jul-2026
Web References: https://menopause.org/wp-content/uploads/press-release/MENO-D-25-00558.pdf
References: 10.1097/GME.0000000000000002837
Image Credits:
Keywords: perimenopause uncertainty, menopause transition, symptom attribution, health literacy, barriers to care, women’s health
Tags: age-related hormonal changes in womenbiological markers of perimenopausehormone-driven menopausal transitionimpact of information access on menopause understandinginfluence of healthcare access on menopausal symptomsmenopause and mental healthperimenopause stage identification challengesPerimenopause symptom variabilitypopulation-level measures of perimenopause uncertaintysymptom overlap with other conditionsunderrecognized reproductive health changeswomen’s health awareness
